Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

What are Endogenous Opioids?

Skip to: - The endogenous opioid system - What roles does the system play? - Endogenous opioids and addiction - Post-operative pain and endogenous endorphins Before scientists discovered endogenous opioids in the 1970s, opioids were only understood in terms of

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

Skip to:

  • The endogenous opioid system
  • What roles does the system play?
  • Endogenous opioids and addiction
  • Post-operative pain and endogenous endorphins

Before scientists discovered endogenous opioids in the 1970s, opioids were only understood in terms of the effects that opioid drugs have, such as inducing sleep, relieving pain, and causing addiction.

After studying various opium extracts, scientists started to realize that the differential effects that they would have must be accounted for by the presence of endogenous opioid receptors. This led them to begin searching for endogenous opioid ligands and the receptors they bind to.

The endogenous opioid system

Since then, researchers have discovered the endogenous opioid system and its significance in day-to-day function and survival, as well as how these should be taken into account when considering opioid drug regimens.

The system comprises three families of opioid peptides - neurotransmitters that are derived from proteolytic cleavage of more abundant precursor proteins - and three families of receptors. The three families of peptides are β-endorphin (derived from the precursor proopiomelanocortin); leucine (Leu)- and methionine (Met)-enkephalins (derived from preproenkephalin); and dynorphins, including dynorphins A and B and neoendorphins (all derived from preprodynorphin).

These opioid peptides bind to their G-protein-coupled receptors - the µ-opioid receptors, the δ-opioid receptors, the κ-opioid receptors, and the non-opioid receptor nociceptin (NOC - previously called opioid receptor-like 1 receptors).

β-endorphin mainly binds to µ-opioid receptors; the Met- and Leu-enkephalins primarily bind to δ-opioid receptors and µ-opioid receptors, while dynorphin and related peptides mainly bind to κ-opioid receptors. Nociceptin/orphanin FQ is the peptide that binds to NOC.

What roles does the system play?

The endogenous opioids and their receptors are widely distributed throughout the central and peripheral nervous systems, particularly the parts of these systems that regulate pain, emotion, reward, stress responses, motivation, drug addiction, and autonomic control. The differential expression and location of the various receptor subtypes across different neurons account for the wide range of opioid-related behaviors. The activation of µ-opioid receptors is mainly known for playing a role in pain relief. Still, research has also indicated it may be involved in behaviors related to survival, such as appetite and reproduction. The activity of µ-opioid receptors is also known to play a critical role in responses to social stimuli by modulating responses to social rejection or social acceptance, for example. Activation of the δ-opioid receptors and κ-opioid receptors is also known to be involved in pain modulation. Also, studies have shown that NOP activation is involved in pain mechanisms and several behaviors related to psychological stress. Alterations in the endogenous opioid system are suspected to be involved in Parkinson's disease, seizures, neuroprotective mechanisms, and depression.

Endogenous opioids and addiction

Since the discovery of the endogenous opioid system, researchers have established its role in addiction. Drug addiction is characterized by adaptive alterations in the brain's reward circuits. Endogenous opioids and their receptors modulate dopaminergic activity and the cortisol response to stress, both of which are involved in the reward response to drugs and alcohol.

Research has shown that long-term use of exogenous opiates causes a comparative deficiency in endogenous endorphins, which, in turn, leads to opiate seeking and contributes to the ongoing relapses seen in cases of addiction.

Further studies using animal models of addiction have demonstrated that the endogenous opioid system significantly influences the effects that addictive substances have. This has also been confirmed in human studies showing that variants in genes that encode opioid system components are associated with the risk of addiction to opiates, cocaine, and alcohol.

Research has shown that many drugs of abuse increase the concentration of dopamine in a brain region called the nucleus accumbens and it has been suggested that this may mediate the rewarding effects these substances have.

Post-operative pain and endogenous endorphins

Opioid drugs are commonly prescribed for post-operative pain, however, these medications adversely affect the body's natural pain management system by disrupting the function of µ-opioid receptors and inhibiting the release of β-endorphin.

In response to post-operative pain, the hypothalamus secretes corticotrophin-releasing hormone, which travels to the anterior pituitary gland, where it triggers the cleavage of proopiomelanocortin to generate β-endorphin. In the peripheral nervous system, the binding of β-endorphin to its µ-opioid receptor and its subsequent activation disinhibits the release of gamma-aminobutyric acid (GABA). This then inhibits the release of neurokinin 1, a protein involved in pain transmission. In the central nervous system, activation of the µ-opioid receptor by β-endorphin inhibits the release of GABA, which usually inhibits the release of dopamine. Consequently, there is an increase in the production of dopamine – the hormone associated with feelings of euphoria.

In post-operative pain, the effect of β-endorphin >is, therefore two-fold – it decreases pain and helps to induce a sense of pleasure, motivation, and well-being.

Since prescriptions opioids stop the production of β-endorphin and disrupt the function of µ-opioid receptors, their administration can prolong and intensify pain, as well as reduce feelings of well-being. This has prompted many doctors to seek alternative pain-relief regimens for post-operative patients, and researchers are investigating non-opioid approaches to pain control.

However, acute post-operative pain and pain related to traumatic injury can be quite serious, and physicians should not withhold pain relief using opioids when used in the short-term. Pharmacologic pain relief can be a useful adjunct when used to help patients return to normal functioning. Long-term use of opioids is not recommended when alternatives are available.

Sources

  • Benarroch, E. Endogenous opioid systems. Current concepts and clinical correlations. Neurology 2012; 79 (8). DOI: https://doi.org/10.1212/WNL.0b013e3182662098. Available at: https://n.neurology.org/content/79/8/807
  • Maldonado, R et al. The endogenous opioid system: A common substrate in drug addiction. Drug and Alcohol Dependence 2010; 108 (3): 183-194. https://doi.org/10.1016/j.drugalcdep.2009.10.011. Available at: www.sciencedirect.com/science/article/abs/pii/S0376871609004013
  • Wand, GS et al. Chapter 4 - Endogenous Opiates, Addiction, and the Stress Response. Stress and Addiction. Biological and Psychological Mechanism 2007, Pages 85-104. https://doi.org/10.1016/B978-012370632-4/50007-3. Available at: www.sciencedirect.com/.../B9780123706324500073?via%3Dihub
  • Zubieta, J et al. Endogenous opioid system dysregulation in depression: implications for new therapeutic approaches. Molecular Psychiatry 2019; 24: 576–587 (2019). doi:10.1038/s41380-018-0117-2. Available at: https://www.nature.com/articles/s41380-018-0117-2
  • Kreek, MJ. Endogenous opioid system in addiction and addiction-related behaviors. Current Opinion in Behavioral Sciences 2017; 13: 196 -202. https://doi.org/10.1016/j.cobeha.2016.12.002 Available at: https://www.sciencedirect.com/science/article/pii/S2352154616302649
  • Sullivan, MD and Ballantyne, JC. Discovery of endogenous opioid systems: what it has meant for the clinician's understanding of pain and its treatment. Pain 2017; 158(12): 2290-2300. doi: 10.1097/j.pain.0000000000001043 Available at: journals.lww.com/.../..._of_endogenous_opioid_systems___what_it.5.aspx
  • Parsa, FD and Stephan, BC. Avoiding Opioids and Their Harmful Side Effects in the Post-operative Patient: Exogenous Opioids, Endogenous Endorphins, Wellness, Mood, and Their Relation to Post-operative Pain. Hawaii J Med Public Health 2016;75(3): 63–67. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4795331/

Last Updated: Feb 17, 2020

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Related questions

01What would be the impact on cancer patients if COTI-2 does prove to be effective in people with p53 mutant tumours?

Given the central role of p53 mutations in human cancers, COTI-2 could represent a breakthrough therapy for many cancer patients if clinical trials confirm its’ activity in people. If we consider a specific disease such as ovarian cancer, p53 mutations are found in more than 90% of these tumours. Preclinical animal experiments with a human ovarian cancer known to have a p53 mutation and be resistant to conventional chemotherapy demonstrated that treatment with COTI-2 as a single agent either completely halted tumour growth or lead to dramatic tumour regression depending on the dose. COTI-2 was associated with no observable toxicity in these experiments.

Source: www.news-medical.net ↗
02Taking both of the topics that we have discussed into consideration, where would you like your research to lead into the future?

As in the past, I hope the new technologies and new knowledge will be useful in the future. It is also important because, in doing my research, the next generation of scientists are educated and can continue such work long after I am gone. That is how science advances, often dragging humanity up and along with it.

Source: www.news-medical.net ↗
03Are there more complex motifs?

These α-helices and β-sheets are not only joined by loops and β-turns but can also be joined by a β-sheet or an α-helix. Metal ions can also play a role in the formation of motifs.

Source: www.news-medical.net ↗
04Your early research focused on predicting molecular properties such as solubility using machine learning. What did that teach you about data-driven property prediction?

Data-driven models, such as Quantitative Structure Activity Relationships (QSAR), are incredibly attractive because they offer rapid methods for predicting molecular properties, including those that are difficult to access through fundamental chemical and physical theory. For new molecules, in related regions of chemical space to the training data, they can often be very accurate. The challenge is that they typically do not generalize across large diverse chemical and biological spaces. Therefore real care is needed when applying them to novel chemistry or biology. Some attempts to build more widely applicable QSAR models have been made in recent years, but most models in use today are still built for specific chemistries and properties owing to the scale and complexity of chemical space. When I started this work, especially for solubility predictions, the datasets were modest by today’s standards, often hundreds to a few thousand molecules. One of the first things that teaches you is to explore the data carefully, assess its quality and quantity, and only then move forward with modeling. The aim is to capture genuine relationships between numerical molecular descriptions and important target endpoints, but those relationships may be only locally generalizable. I also think the phrase “simple descriptors” is interesting. Some are simple, such as atom counts or bond counts, but others rely on detailed parameterization, group contributions, and graph-theoretical techniques. We still see these descriptors used today, sometimes alongside embeddings from graph neural networks or language models. The main lesson for me is that there is no single workflow. Each dataset, model, and end-use case needs careful thought.

Source: www.news-medical.net ↗
05What's next?

Stupp's team is currently testing these systems in animal studies and adding additional signals to create highly bioactive therapies. "With the success of the study in human cartilage cells, we predict that cartilage regeneration will be greatly enhanced when used in highly translational pre-clinical models," Stupp said. "It should develop into a novel bioactive material for regeneration of cartilage tissue in joints." Stupp's lab is also testing the ability of dancing molecules to regenerate bone - and already has promising early results, which likely will be published later this year. Simultaneously, he is testing the molecules in human organoids to accelerate the process of discovering and optimizing therapeutic materials. Stupp's team also continues to build its case to the Food and Drug Administration, aiming to gain approval for clinical trials to test the therapy for spinal cord repair. "We are beginning to see the tremendous breadth of conditions that this fundamental discovery on 'dancing molecules' could apply to," Stupp said. "Controlling supramolecular motion through chemical design appears to be a powerful tool to increase efficacy for a range of regenerative therapies." The study, "Supramolecular motion enables chondrogenic bioactivity of a cyclic peptide mimetic of transforming growth factor-β1," was supported by a gift from Mike and Mary Sue Shannon to Northwestern University for research on musculoskeletal regeneration at the Center for Regenerative Nanomedicine of the Simpson Querrey Institute for BioNanotechnology. Yuan, S. C., et al. (2024). Supramolecular Motion Enables Chondrogenic Bioactivity of a Cyclic Peptide Mimetic of Transforming Growth Factor-β1. Journal of the American Chemical Society. doi.org/10.1021/jacs.4c05170

Source: www.news-medical.net ↗
comparison

Comparisons

Side-by-side pages for commonly compared peptides and research compounds.

Source: peptideuniv.com
Research context

Read sources and limitations before applying a claim.

Longevity, Performance & Obesity Research

A research peptide formulation developed to investigate metabolic regulation, mitochondrial function, and nutrient-sensing pathways.

Source: mypeptidematch.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →